866-997-4948(US-Canada Toll Free)

Companion Diagnostic Tests in Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Published By :

Transparency

Published Date : Jun 2017

Category :

Biotechnology

No. of Pages : 232 Pages

Global Companion Diagnostic Tests in Oncology Market: Overview

Companion diagnostics (CDx) are the tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with a targeted therapeutic area. These tests are an indicative measure of the patient sub-population that will be benefitted from the suggested drug / therapy, and differentiates the non-responder patients from the one’s who will respond to the treatment option. Hence, these diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to pharmaceutical companies, and the patients as well. Of late, many leading pharmaceutical companies are focusing on regulating the costs incurred in the drug discovery, development and commercialization process. This effort involves the development of companion diagnostic along with a targeted therapeutic area, and this has led to increasing collaborations between pharmaceutical and medical device companies, to co-develop a drug with companion diagnostic test. The tremendous research in the field of oncology, has led to the discovery of numerous biomarkers facilitating disease diagnosis and treatment, and these are some major factors contributing to the increasing demand for personalized medicine, and companion diagnostics tests in oncology.

The market overview section of the report comprises qualitative analysis of the overall companion diagnostic tests in oncology market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, market opportunity analysis for detection techniques, biomarker, and type of cancer, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics.

Global Companion Diagnostic Tests in Oncology Market: Segmentation

The global companion diagnostic tests in oncology market has been segmented on the basis of detection technique, biomarker, cancer type, and end-user. On the basis of detection technique, the global companion diagnostic tests in oncology market is segmented into protein detection technique, DNA detection technique, and other detection techniques.  The DNA detection techniques are further segmented into polymerase chain reaction, next generation sequencing, and in situ hybridization detection techniques. The biomarker segment of the global companion diagnostic tests in oncology market is segmented into EGFR, HER2, KRAS, BRAF V600E, and other biomarkers. The cancer type segment of the global companion diagnostic tests in oncology market is further segmented into breast cancer, lung cancer, liver cancer, melanoma, colorectal cancer, and other cancers. The end-user segment includes pharmaceutical & biotechnology companies, medical device companies, research institutes, and other end-users. The market for these detection techniques, biomarker, cancer types and end users has been extensively analyzed on the basis of factors such as incidence, prevalence of diseases, usage pattern of detection techniques, sales revenue of the tests, geographic presence of the market players and technological developments. The market size and forecast in terms of revenue (US$ Mn) for each of these segments have been provided for the period 2015 to 2025, considering 2016 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2017 to 2025.

Global Companion Diagnostic Tests in Oncology Market: Regional Outlook

Geographically, the companion diagnostic tests in oncology market has been segmented into five regions namely; North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of detection techniques, biomarker, cancer type, and end-user along with the CAGR (%) for the forecast period 2017-2025.

Global Companion Diagnostic Tests in Oncology Market: Competitive Landscape

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global companion diagnostic tests in oncology market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global Companion Diagnostic Tests in Oncology market such as F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global companion diagnostic tests in oncology market is segmented as follows:

Global Companion Diagnostic Tests in Oncology Market, By Detection Technique

  • Protein Detection
  • DNA Detection
  • Polymerase Chain Reaction (PCR)
  • Next Gen Sequencing (NGS)
  • In Situ Hybridization
  • Fluorescence In Situ Hybridization (FISH)
  • Chromogenic In Situ Hybridization (CISH)
  • Others

Global Companion Diagnostic Tests in Oncology Market, by Biomarker

  • EGFR
  • KRAS
  • HER2
  • BRAF V600E
  • Others

Global Companion Diagnostic Tests in Oncology Market, by Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Melanoma
  • Others

Global Companion Diagnostic Tests in Oncology Market, by End Users

  • Pharmaceutical & Biotechnology Companies
  • Medical Device Companies
  • Research Institutes
  • Others

Global Companion Diagnostic Tests in Oncology Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Table of Content

1. Preface 
1.1. Market Definition and Scope 
1.2. Market Segmentation 
1.3. Key Research Objectives 
1.4. Research Highlights 

2. Assumptions and Research Methodology 

3. Executive Summary : Global Digital Companion Diagnostics Market 

4. Market Overview 
4.1. Introduction 
4.1.1 Detection Technique Definition 
4.1.2 Industry Evolution / Developments 
4.2. Overview 
4.3. Key Market Indicators 
4.4. Market Dynamics 
4.4.1 Drivers 
4.4.2 Restraints 
4.4.3 Opportunity 
4.5. Global Digital Companion Diagnostics MarketAnalysis and Forecasts, 2015–2025 
4.5.1 Market Revenue Projections (US$ Mn) 
4.6. Porter’s Five Force Analysis 
4.7. Market Outlook 
4.8. Future Trends: response-guided therapy, theranostic 
4.9. FDA breakthrough therapies: For Companion Diagnostic Tests 
4.10. Overview FDA approved in-vitro Companion Diagnostic Tests 
4.11. Companion Diagnostics and regulatory requirements : regionwise 
4.12. Companion Diagnostic Tests - Intended Diagnostics Type - Market Players
4.13. Pipeline Overview: Major market players 

5. Global Digital Companion Diagnostics MarketAnalysis and Forecasts, By Detection Technique
5.1. Introduction & Definition 
5.2. Key Findings / Developments 
5.3. Key Trends 
5.4. Market Value Forecast By Detection Technique , 2015–2025 
5.4.1 Protein Detection 
5.4.1.1 Immunohistochemistry 
5.4.2 DNA Detection 
5.4.2.1 Polymerase Chain Reaction 
5.4.2.2 Next Gen Sequencing 
5.4.2.3 In-Situ Hybridization 
5.4.3 Others 
5.5. Market Attractiveness By Detection Technique

6. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Bio-markers
6.1. Introduction & Definition 
6.2. Key Findings / Developments 
6.3. Key Trends 
6.4. Market Value Forecast By Bio-markers, 2015–2025 
6.4.1. EGFR 
6.4.2. KRAS 
6.4.3. BRAF V600E 
6.4.4. HER2 
6.4.5. Others 
6.5. Market Attractiveness By Bio-markers

7. Global Digital Companion Diagnostics MarketAnalysis and Forecasts, By Cancer Type
7.1. Introduction & Definition 
7.2. Key Findings / Developments 
7.3. Key Trends 
7.4. Market Value Forecast By Cancer Type , 2015–2025 
7.4.1 Breast Cancer 
7.4.2 Liver Cancer 
7.4.3 Lung Cancer 
7.4.4 Colorectal Cancer 
7.4.5 Melanoma 
7.4.6 Others
7.5. Market Attractiveness By Cancer Type

8. Global Digital Companion Diagnostics MarketAnalysis and Forecasts, By End User 
8.1. Introduction & Definition 
8.2. Key Findings / Developments 
8.3. Key Trends 
8.4. Market Value Forecast By End User , 2015–2025 
8.4.1 Hospitals 
8.4.2 Specialty Clinics 
8.4.3 Diagnostic Labs 
8.4.4 Others 
8.5. Market Attractiveness By End User

9. Global Digital Companion Diagnostics MarketAnalysis and Forecasts, By Region 
9.1. Key Findings 
9.2. Policies and Regulations 
9.3. Market Value Forecast By Region 
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Latin America
9.3.5 Middle East and Africa
9.4. Market Attractiveness By Country/Region 

10. North America Digital Companion Diagnostics MarketAnalysis and Forecast
10.1. Introduction 
10.1.1 Key Findings 
10.1.2 Policies and Regulations 
10.1.3 Key Trends 
10.2. Market Value Forecast By Detection Technique, 2015–2025 
10.2.1 Protein Detection 
10.2.1.1 Immunohistochemistry 
10.2.2 DNA Detection 
10.2.2.1 Polymerase Chain Reaction 
10.2.2.2 Next Gen Sequencing 
10.2.2.3 In-Situ Hybridization 
10.2.3 Others 
10.3. Market Value Forecast By Bio-markers, 2015–2025 
10.3.1 EGFR 
10.3.2 KRAS 
10.3.3 BRAF V600E 
10.3.4 HER2 
10.3.5 Others 
10.4. Market Value Forecast By Cancer Type , 2015–2025 
10.4.1 Breast Cancer 
10.4.2 Liver Cancer 
10.4.3 Lung Cancer 
10.4.4 Colorectal Cancer 
10.4.5 Melanoma 
10.4.6 Others
10.5. Market Value Forecast By End User , 2015–2025 
10.5.1 Hospitals 
10.5.2 Specialty Clinics 
10.5.3 Diagnostic Labs 
10.5.4 Others 
10.6. Market Value Forecast By Country , 2015–2025 
10.6.1 U.S. 
10.6.2 Canada 
10.6. Market Attractiveness Analysis
10.6.1 By Detection Technique
10.6.2 By Bio-markers
10.6.3 By Cancer Type
10.6.4 By End User
10.6.5 By Country 

11. Europe Digital Companion Diagnostics MarketAnalysis and Forecast 11.1. Introduction 
11.1.1 Key Findings 
11.1.2 Policies and Regulations 
11.1.3 Key Trends 
11.2. Market Value Forecast By Detection Technique , 2015–2025 
11.2.1 Protein Detection 
11.2.1.1 Immunohistochemistry 
11.2.2 DNA Detection 
11.2.2.1 Polymerase Chain Reaction 
11.2.2.2 Next Gen Sequencing 
11.2.2.3 In-Situ Hybridization 
11.2.3. Others 
11.3. Market Value Forecast By Bio-markers , 2015–2025 
11.3.1 EGFR 
11.3.2 KRAS 
11.3.3 BRAF V600E 
11.3.4 HER2 
11.3.5 Others 
11.4. Market Value Forecast By Cancer Type , 2015–2025 
11.4.1 Breast Cancer 
11.4.2 Liver Cancer 
11.4.3 Lung Cancer 
11.4.4 Colorectal Cancer 
11.4.5 Melanoma 
11.4.6 Others
11.5. Market Value Forecast By End User , 2015–2025 
11.5.1 Hospitals 
11.5.2 Specialty Clinics 
11.5.3 Diagnostic Labs 
11.5.4 Others 
11.6. Market Value Forecast By Country , 2015–2025 
11.6.1 U.K. 
11.6.2 Germany 
11.6.3 France 
11.6.4 Italy 
11.6.5 Spain 
11.6.6 Russia 
11.6.7 Rest of Europe 
11.7. Market Attractiveness Analysis
11.7.1 By Detection Technique
11.7.2 By Bio-markers
11.7.3 By Cancer Type
11.7.4 By End User
11.7.5 By Country 

12. Asia Pacific Digital Companion Diagnostics MarketAnalysis and Forecast 12.1. Introduction 
12.1.1 Key Findings 
12.1.2 Policies and Regulations 
12.1.3 Key Trends 
12.2. Market Value Forecast By Detection Technique , 2015–2025 
12.2.1 Protein Detection 
12.2.1.1 Immunohistochemistry 
12.2.2 DNA Detection 
12.2.2.1 Polymerase Chain Reaction 
12.2.2.2 Next Gen Sequencing 
12.2.2.3 In-Situ Hybridization 
12.2.3 Others 
12.3. Market Value Forecast By Bio-markers , 2015–2025 
12.3.1 EGFR 
12.3.2 KRAS 
12.3.3 BRAF V600E 
12.3.4 HER2 
12.3.5 Others 
12.4. Market Value Forecast By Cancer Type , 2015–2025 
12.4.1 Breast Cancer 
12.4.2 Liver Cancer 
12.4.3 Lung Cancer 
12.4.4 Colorectal Cancer 
12.4.5 Melanoma 
12.4.6 Others
12.5. Market Value Forecast By End User , 2015–2025 
12.5.1 Hospitals 
12.5.2 Specialty Clinics 
12.5.3 Diagnostic Labs 
12.5.4 Others 
12.6. Market Value Forecast By Country , 2015–2025 
12.6.1 India 
12.6.2 China 
12.6.3 Japan 
12.6.4 Australia & New Zealand 
12.6.5 Rest of Asia Pacific 
12.7. Market Attractiveness Analysis
12.7.1 By Detection Technique
12.7.2 By Bio-markers
12.7.3 By Cancer Type
12.7.4 By End User
12.7.5 By Country 

13. Latin America Digital Companion Diagnostics MarketAnalysis and Forecast 
13.1. Introduction 
13.1.1 Key Findings 
13.1.2 Policies and Regulations 
13.1.4 Key Trends 
13.2. Market Value Forecast By Detection Technique , 2015–2025 
13.2.1 Protein Detection 
13.2.1.1 Immunohistochemistry 
13.2.2 DNA Detection 
13.2.2.1 Polymerase Chain Reaction 
13.2.2.2 Next Gen Sequencing 
13.2.2.3 In-Situ Hybridization 
13.2.3 Others 
13.3. Market Value Forecast By Bio-markers , 2015–2025 
13.3.1 EGFR 
13.3.2 KRAS 
13.3.3 BRAF V600E 
13.3.4 HER2 
13.3.5 Others 
13.4. Market Value Forecast By Cancer Type , 2015–2025 
13.4.1 Breast Cancer 
13.4.2 Liver Cancer 
13.4.3 Lung Cancer 
13.4.4 Colorectal Cancer 
13.4.5 Melanoma 
13.4.6 Others
13.5. Market Value Forecast By End User , 2015–2025 
13.5.1 Hospitals 
13.5.2 Specialty Clinics 
13.5.3 Diagnostic Labs 
13.5.4. Others 
13.6. Market Value Forecast By Country , 2015–2025 
13.6.1 Brazil 
13.6.2 Mexico 
13.6.3 Rest of Latin America 
13.7. Market Attractiveness Analysis
13.7.1 By Detection Technique
13.7.2 By Bio-markers
13.7.3 By Cancer Type
13.7.4 By End User
13.7.5 By Country 

14. Middle East and Africa Digital Companion Diagnostics MarketAnalysis and Forecast 
14.1. Introduction 
14.1.1 Key Findings 
14.1.2 Policies and Regulations 
14.1.4 Key Trends 
14.2. Market Value Forecast By Detection Technique , 2015–2025 
14.2.1 Protein Detection 
14.2.1.1 Immunohistochemistry 
14.2.2 DNA Detection 
14.2.2.1 Polymerase Chain Reaction 
14.2.2.2 Next Gen Sequencing 
14.2.2.3 In-Situ Hybridization 
14.2.3 Others 
14.3. Market Value Forecast By Bio-markers , 2015–2025 
14.3.1 EGFR 
14.3.2 KRAS 
14.3.3 BRAF V600E 
14.3.4 HER2 
14.3.5 Others 
14.4. Market Value Forecast By Cancer Type , 2015–2025 
14.4.1 Breast Cancer 
14.4.2 Liver Cancer 
14.4.3 Lung Cancer 
14.4.4 Colorectal Cancer 
14.4.5 Melanoma 
14.4.6 Others
14.5. Market Value Forecast By End User , 2015–2025 
14.5.1 Hospitals 
14.5.2 Specialty Clinics 
14.5.3 Diagnostic Labs 
14.5.4 Others 
14.6. Market Value Forecast By Country , 2015–2025 
14.6.1 South Africa 
14.6.2 GCC Countries 
14.6.3 Rest of Middle East and Africa 
14.7. Market Attractiveness Analysis
14.7.1 By Detection Technique
14.7.2 By Bio-markers
14.7.4 By Cancer Type
14.7.5 By End User
14.7.6 By Country 

15. Competition Landscape
15.1 Market Player – Competition Matrix (By Tier and Size of companies)
15.2 Market Share Analysis By Company (2015)
15.3 Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1 Abbott
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.1.2 Financial Overview
15.3.1.3 Product Portfolio
15.3.1.4 SWOT Analysis
15.3.1.5 Strategic Overview
15.3.2 F. Hoffman LA Roche Ltd. 
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.2.2 Financial Overview
15.3.2.3 Product Portfolio
15.3.2.4 SWOT Analysis
15.3.2.5 Strategic Overview
15.3.3 Genomic Health, Inc.
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.3.2 Financial Overview
15.3.3.3 Product Portfolio
15.3.3.4 SWOT Analysis
15.3.3.5 Strategic Overview
15.3.4 QIAGEN
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.4.2 Financial Overview
15.3.4.3 Product Portfolio
15.3.4.4 SWOT Analysis
15.3.4.5 Strategic Overview
15.3.5 Agilent Technologies, Inc.
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.5.2 Financial Overview
15.3.5.3 Product Portfolio
15.3.5.4 SWOT Analysis
15.3.5.5 Strategic Overview
15.3.6 AGENDIA NV
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.6.2 Financial Overview
15.3.6.3 Product Portfolio
15.3.6.4 SWOT Analysis
15.3.6.5 Strategic Overview
15.3.7 bioMerieux SA
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.7.2 Financial Overview
15.3.7.3 Product Portfolio
15.3.7.4 SWOT Analysis
15.3.7.5 Strategic Overview
15.3.8 Illumina, Inc.
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.8.2 Financial Overview
15.3.8.3 Product Portfolio
15.3.8.4 SWOT Analysis
15.3.8.5 Strategic Overview
15.3.9 Siemens Healthcare GmBH
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.9.2 Financial Overview
15.3.9.3 Product Portfolio
15.3.9.4 SWOT Analysis
15.3.9.5 Strategic Overview
15.3.10 Thermo Fisher Scientific, Inc.
15.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.10.2 Financial Overview
15.3.10.3 Product Portfolio
15.3.10.4 SWOT Analysis
15.3.10.5 Strategic Overview
15.3.11 BioGenex
15.3.11.1 Company Overview (HQ, Business Segments, Employee Strengths)
15.3.11.2 Financial Overview
15.3.11.3 Product Portfolio
15.3.11.4 SWOT Analysis
15.3.11.5 Strategic Overview

List of Table

Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 06: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 07: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 09: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 11: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 12: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 13: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 14: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 16: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 17: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 18: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 19: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 20: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 21: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 22: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 23: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique,
Table 24: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 25: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 26: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 27: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 28: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 29: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 30: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 31: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 32: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 33: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 34: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 35: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 36: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 37: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 38: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 39: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 40: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 41: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 42: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025

List of Chart

Figure 01: Global Companion Diagnostic Tests in Oncology, Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type (2016)
Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker (2016)
Figure 04: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique (2016)
Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region (2016)
Figure 06: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user (2016)
Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 08: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 09: Global Protein Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 10: Global DNA Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Global Other Detection Techniques in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 14: Global Companion Diagnostic Tests in Oncology Market, by EGFR Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 15: Global Companion Diagnostic Tests in Oncology Market, by KRAS Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 16: Global Companion Diagnostic Tests in Oncology Market, by BRAF V600E Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 17: Global Companion Diagnostic Tests in Oncology Market, by HER2 Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 18: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 19: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 20: Global Companion Diagnostic Tests in Oncology Market, by Breast Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 21: Global Companion Diagnostic Tests in Oncology Market, by Lung Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 22: Global Companion Diagnostic Tests in Oncology Market, by Liver Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: Global Companion Diagnostic Tests in Oncology Market, by Colorectal Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 24: Global Companion Diagnostic Tests in Oncology Market, by Melanoma Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 25: Global Companion Diagnostic Tests in Oncology Market, by Other Cancers, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 26: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 27: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 28: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Pharmaceutical & Biotechnology Companies, 2015–2025
Figure 29: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Medical Device Companies, 2015–2025
Figure 30: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Research Laboratories, 2015–2025
Figure 31: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Others, 2015–2025
Figure 32: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2017 and 2025 
Figure 33: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Region, 2017–2025
Figure 34: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 35: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025
Figure 36: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 37: North America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 38: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 39: North America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 40: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 41: North America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 42: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 43: North America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 44: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 45: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 46: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
Figure 47: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 48: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 49: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 50: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 51: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 52: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 53: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 54: Europe Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 55: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 56: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 57: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
Figure 58: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 59: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 60: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 61: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 62: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 63: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 64: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 65: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 66: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 67: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 68: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
Figure 69: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 70: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 71: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 72: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 73: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 74: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 75: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 76: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 77: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 78: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 79: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025 
Figure 80: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2017–2025
Figure 81: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2017 and 2025
Figure 82: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2017–2025
Figure 83: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 84: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 85: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2017 and 2025
Figure 86: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2017–2025
Figure 87: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2017 and 2025
Figure 88: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2017–2025
Figure 89: Global Companion Diagnostic Tests in Oncology Market Share, by Company, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *